Vitamin B3 for recent onset leber's hereditary optic neuropathy
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether vitamin B3 (nicotinamide) can help people with a rare inherited eye condition called Leber's Hereditary Optic Neuropathy (LHON). The goal is to see if taking this vitamin can slow or improve vision loss, especially when started soon after symptoms appear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be at least 16 years old
- Diagnosed with LHON from one of two specific gene changes (m.11778G>A or m.3460G>A)
- Your vision problems started less than 18 months ago
- You have not taken idebenone or nicotinamide in the past 3 months
- You can take oral medication and attend study visits
- You have not had gene therapy for LHON
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy injection into the eye to improve vision in people with a specific type of inherited optic nerve disease called Leber’s hereditary optic neuropathy (LHON). It is aimed at people who have a particular genetic change and a history of vision loss lasting long enough to measure change, while checking for safety first.
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
This trial tests whether a vitamin B3 supplement called nicotinamide can help slow down vision loss in people with glaucoma. It is for those with moderate disease who are already on treatment.
This trial tests whether nicotinamide (a form of vitamin B3) can slow vision changes from open-angle glaucoma. It compares nicotinamide versus a placebo (inactive pill) in adults with early to moderate disease.
This study tests whether a daily vitamin B3 pill (called nicotinamide) can help protect the optic nerve and slow down vision loss in people with glaucoma. If you're already managing glaucoma with eye drops or laser, this could be an option to preserve your sight.
This trial studies whether nicotinamide (a form of vitamin B3/niacin) can slow or affect glaucoma progression. You may be eligible if you have newly diagnosed, untreated glaucoma or if you have treated glaucoma with measurable visual field changes.
Hear when a new Leber Hereditary Optic Neuropathy (LHON) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.